Variant in Sex Hormone-Binding Globulin Gene and the Risk of Prostate Cancer

Sex hormones have been implicated in prostate carcinogenesis and are thought to modulate cell proliferation and growth. To investigate the association between polymorphisms in hormone-related genes and prostate cancer risk, we conducted a two-stage, case-control study within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Using DNA extracted from blood specimens, we initially genotyped 14 single nucleotide polymorphisms in genes involved in hormone regulation or metabolism (AKR1C3, CYP1A1, CYP1B1, CYP3A4, ESR1, GNRH1, HSD173B, HSD3B2, SHBG, and SRD5A2) in 488 prostate cancer cases and 617 matched controls. Heterozygotes at SHBG D356N were found to be associated with an increased risk of prostate cancer compared with the homozygous wild type, particularly among non-Hispanic whites (odds ratio, 1.54; 95% confidence interval, 1.13-2.09; P = 0.006). No significant associations were observed with the other polymorphisms. The SHBG D356N polymorphism, which has potential functional significance, was subsequently genotyped in additional 769 cases and 1,168 controls. Overall, SHBG D356N heterozygotes were found to have an increased risk of prostate cancer among whites (odds ratio, 1.34; 95% confidence interval, 1.10-1.63; P = 0.0007). This study suggests that genetic variation in SHBG may influence prostate cancer susceptibility. (Cancer Epidemiol Biomarkers Prev 2007;16(1):165–8)

[1]  G. Hammond,et al.  Evidence That Fibulin Family Members Contribute to the Steroid-dependent Extravascular Sequestration of Sex Hormone-binding Globulin* , 2006, Journal of Biological Chemistry.

[2]  Robert N Hoover,et al.  Methods for etiologic and early marker investigations in the PLCO trial. , 2005, Mutation research.

[3]  L. Leung,et al.  Enhanced induction of prostatic dysplasia and carcinoma in Noble rat model by combination of neonatal estrogen exposure and hormonal treatments at adulthood. , 2005, International journal of oncology.

[4]  H. Schulz,et al.  Role of Endocytosis in Cellular Uptake of Sex Steroids , 2005, Cell.

[5]  D. Carmelli,et al.  Heritability of plasma sex hormones and hormone binding globulin in adult male twins. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  C. Haiman,et al.  Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating shbg levels among postmenopausal women: the Multiethnic Cohort. , 2005, The Journal of clinical endocrinology and metabolism.

[7]  I. Roots,et al.  Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. , 2005, Cancer research.

[8]  W. Weimar,et al.  Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR‐1, CYP3A4, and CYP3A5 genes , 2004, Clinical pharmacology and therapeutics.

[9]  Y. Morel,et al.  Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. , 2004, The Journal of clinical endocrinology and metabolism.

[10]  P. Stattin,et al.  High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study , 2004, International journal of cancer.

[11]  Brian Staats,et al.  SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes , 2004, Nucleic Acids Res..

[12]  B. Ponder,et al.  Polymorphisms associated with circulating sex hormone levels in postmenopausal women. , 2005, Journal of the National Cancer Institute.

[13]  A. Tsatsoulis,et al.  Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. , 2003, European journal of endocrinology.

[14]  A. Tsatsoulis,et al.  Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. , 2003, The Journal of clinical endocrinology and metabolism.

[15]  R. Elston,et al.  Optimal two‐stage genotyping in population‐based association studies , 2003, Genetic epidemiology.

[16]  J. Reichardt,et al.  Hormones and prostate cancer: Current perspectives and future directions , 2002, The Prostate.

[17]  E. Bleecker,et al.  Common Estrogen Receptor Polymorphism Augments Effects of Hormone Replacement Therapy on E-Selectin but Not C-Reactive Protein , 2002, Circulation.

[18]  M. Talikka,et al.  Human Sex Hormone-binding Globulin Promoter Activity Is Influenced by a (TAAAA) n Repeat Element within an Alu Sequence* , 2001, The Journal of Biological Chemistry.

[19]  P C Prorok,et al.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[20]  N. Roodi,et al.  Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. , 2000, Cancer research.

[21]  M. Pugeat,et al.  Human variant sex hormone-binding globulin (SHBG) with an additional carbohydrate chain has a reduced clearance rate in rabbit. , 1998, The Journal of clinical endocrinology and metabolism.

[22]  C. Lewis,et al.  Age, genetic, and nongenetic factors influencing variation in serum sex steroids and zonal volumes of the prostate and benign prostatic hyperplasia in twins , 1997, The Prostate.

[23]  M. Pike,et al.  A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. , 1997, Cancer research.

[24]  M. Webber,et al.  Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications part 2. Tumorigenic cell lines , 1997, The Prostate.

[25]  M. Stampfer,et al.  Prospective study of sex hormone levels and risk of prostate cancer. , 1996, Journal of the National Cancer Institute.

[26]  W. Rosner,et al.  Estradiol causes the rapid accumulation of cAMP in human prostate. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Hammond,et al.  Selective removal of glycosylation sites from sex hormone-binding globulin by site-directed mutagenesis. , 1992, Endocrinology.

[28]  G. Hammond,et al.  Molecular analyses of a human sex hormone-binding globulin variant: evidence for an additional carbohydrate chain. , 1992, The Journal of clinical endocrinology and metabolism.

[29]  J. Yates,et al.  Complete enzymatic deglycosylation of native sex steroid‐binding protein (SBP or SHBG) of human and rabbit plasma: Effect on the steroid‐binding activity , 1992, Protein science : a publication of the Protein Society.

[30]  Joseph T. DiPiro,et al.  Pharmacotherapy: A pathophysiologic approach , 1992 .

[31]  M. S. Khan,et al.  Biologically active steroids activate receptor-bound human sex hormone-binding globulin to cause LNCaP cells to accumulate adenosine 3',5'-monophosphate. , 1990, The Journal of clinical endocrinology and metabolism.

[32]  G. Avvakumov,et al.  Specific steroid-binding glycoproteins of human blood plasma: novel data on their structure and function. , 1990, Journal of steroid biochemistry.

[33]  J. Geller,et al.  Pathogenesis and medical treatment of benign prostatic hyperplasia , 1989, The Prostate. Supplement.

[34]  Morris Pollard,et al.  Prevention and treatment of experimental prostate cancer in lobund‐wistar rats. I. Effects of estradiol, dihydrotestosterone, and castration , 1989, The Prostate.

[35]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[36]  D. West,et al.  Quantitating genetic and nongenetic factors that determine plasma sex steroid variation in normal male twins. , 1986, Metabolism: clinical and experimental.

[37]  M. Sairam,et al.  A role for glycosylation of the alpha subunit in transduction of biological signal in glycoprotein hormones. , 1985, Science.

[38]  L. Daehlin.  On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic carcinoma. , 1985, Scandinavian journal of urology and nephrology. Supplementum.

[39]  R. Noble.  The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. , 1977, Cancer research.